Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
18 juil. 2019 12h40 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, July 18, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
27 juin 2019 12h18 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, June 27, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
05 juin 2019 12h42 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering
04 juin 2019 18h01 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, June 04, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline...
Cotinga Pharmacueticals Announces Closing of Unit Offering
22 mai 2019 17h26 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, May 22, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
08 mai 2019 11h10 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results
05 avr. 2019 13h18 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, April 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering
19 mars 2019 11h00 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline...
Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
26 févr. 2019 11h08 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2
29 janv. 2019 10h21 HE
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...